A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (Valspodar)

Cancer

Volumn 92, Issue 6, 2001, Pages 1577-1590

  Bates, Susan ^a   Kang, Min ^a   Meadows, Beverly ^a   Bakke, Susan ^b   Choyke, Peter ^a   Merino, Maria ^b   Goldspiel, Barry ^a   Chico, Isagani ^c   Smith, Tom ^b   Chen, Clara ^a   Robey, Robert ^a   Bergan, Raymond ^d   Figg, William D ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug resistance reversal; P glycoprotein antagonist; Pharmacokinetic interaction; Renal cell carcinoma

Indexed keywords

CD56 ANTIGEN; GLYCOPROTEIN P; RHODAMINE; VALSPODAR; VINBLASTINE;

ARTICLE; ATAXIA; BIOAVAILABILITY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; FEVER; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MICROEMULSION; MULTIDRUG RESISTANCE; NEUTROPENIA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CYCLOSPORINS; DRUG ADMINISTRATION SCHEDULE; EMULSIONS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; MIDDLE AGED; P-GLYCOPROTEIN; RADIOIMMUNOASSAY; T-LYMPHOCYTES; VINBLASTINE;

EID: 0035883604     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010915)92:6<1577::AID-CNCR1484>3.0.CO;2-H     Document Type: Article

References (45)

1. Chemosensitizers in tumor therapy: New compounds promise better efficacy
2. SDZ PSC 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia
3. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines
4. Chemotherapy for advanced renal-cell carcinoma: 1983-1993
5. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma
6. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer
7. Future perspectives for the development of P-glycoprotein modulators
8. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
9. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
10. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
11. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
12. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice
13. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
14. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain
15. Modulation of vinblastine resistance with cyclosporine: A Phase I study
16. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A Cancer and Leukemia Group B study
17. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist
18. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833
19. Intrinsic drug resistance in primary and metastatic renal cell carcinoma
20. A Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance
21. Optimizing the absorption of valspodar, a P-glycoprotein modulator. Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate
22. Optimizing the absorption of valspodar, a P-glycoprotein modulator. Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics
23. Quality of life in colorectal cancer patients treated with doxorubicin and a multi-drug resistance (MDR) modulator (SDZ PSC-833): A pilot study
24. PSC833: Initial clinical results in refractory ovarian cancer patients
25. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
26. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies
27. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
28. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833
29. Pharmacological considerations in the modulation of multidrug resistance
30. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
31. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A Phase I study
32. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
33. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valspodar)
34. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions
35. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: Implications for coadministration
36. The erythromycin breath test predicts the clearance of midazolam
37. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
38. Drug metabolism by cytochromes P450 in the liver and small bowel
39. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo
40. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
41. Detection of in vivo p-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi
42. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours
43. In vivo detection of multidrug-resistant (MDR1) phenotype by 99m sestamibi scan in untreated breast cancer patients
44. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
45. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?